📊 STTK Key Takeaways
Is Shattuck Labs, Inc. (STTK) a Good Investment?
Shattuck Labs is a pre-commercial biotech company with essentially no revenue (1.0M down 82.5% YoY) and severe operating losses of 51.5M, burning approximately 40M annually in cash. While the balance sheet remains strong with 54.2M cash and minimal debt, current cash runway is only 1-1.5 years at present burn rates, creating material financial distress risk without successful near-term revenue generation or capital raises.
Why Buy Shattuck Labs, Inc. Stock? STTK Key Strengths
- Fortress balance sheet with zero long-term debt and 0.00x debt-to-equity ratio
- Exceptional liquidity position with 11.70x current ratio providing operational flexibility
- Substantial cash reserves of 54.2M provide runway for clinical development and manufacturing scale-up
STTK Stock Risks: Shattuck Labs, Inc. Investment Risks
- Revenue collapse of 82.5% YoY signals deteriorating commercialization or pipeline execution
- Operating cash burn of 40M annually is unsustainable; current cash runway approximately 1.5 years
- Pre-revenue status with massive operating losses suggests company remains years away from profitability
- Inherent biotech execution risk including clinical trial failures and regulatory approval uncertainty
- Dilution risk from inevitable future capital raises needed to extend runway
Key Metrics to Watch
- Cash runway and quarterly burn rate trajectory
- Clinical trial advancement and regulatory milestone achievements
- Revenue growth and path to commercialization
- Capital raise activity and dilution events
- Operating expense management and burn reduction initiatives
Shattuck Labs, Inc. (STTK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.70x current ratio provides a solid financial cushion.
STTK Profit Margin, ROE & Profitability Analysis
STTK vs Healthcare Sector: How Shattuck Labs, Inc. Compares
How Shattuck Labs, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Shattuck Labs, Inc. Stock Overvalued? STTK Valuation Analysis 2026
Based on fundamental analysis, Shattuck Labs, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Shattuck Labs, Inc. Balance Sheet: STTK Debt, Cash & Liquidity
STTK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Shattuck Labs, Inc.'s revenue has declined by 81% over the 5-year period, indicating business contraction. The most recent EPS of $-1.49 indicates the company is currently unprofitable.
STTK Revenue Growth, EPS Growth & YoY Performance
STTK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.0M | -$10.1M | $-0.14 |
| Q2 2025 | N/A | -$12.5M | $-0.24 |
| Q1 2025 | N/A | -$13.7M | $-0.27 |
| Q3 2024 | $686.0K | -$16.7M | $-0.33 |
| Q2 2024 | $200.0K | -$18.5M | $-0.42 |
| Q1 2024 | $57.0K | -$18.5M | $-0.37 |
| Q3 2023 | $212.0K | -$20.7M | $-0.58 |
| Q2 2023 | $50.0K | -$20.7M | $-0.50 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Shattuck Labs, Inc. Dividends, Buybacks & Capital Allocation
STTK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Shattuck Labs, Inc. (CIK: 0001680367)
📋 Recent SEC Filings
❓ Frequently Asked Questions about STTK
What is the AI rating for STTK?
Shattuck Labs, Inc. (STTK) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are STTK's key strengths?
Claude: Fortress balance sheet with zero long-term debt and 0.00x debt-to-equity ratio. Exceptional liquidity position with 11.70x current ratio providing operational flexibility.
What are the risks of investing in STTK?
Claude: Revenue collapse of 82.5% YoY signals deteriorating commercialization or pipeline execution. Operating cash burn of 40M annually is unsustainable; current cash runway approximately 1.5 years.
What is STTK's revenue and growth?
Shattuck Labs, Inc. reported revenue of $1.0M.
Does STTK pay dividends?
Shattuck Labs, Inc. does not currently pay dividends.
Where can I find STTK SEC filings?
Official SEC filings for Shattuck Labs, Inc. (CIK: 0001680367) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is STTK's EPS?
Shattuck Labs, Inc. has a diluted EPS of $-0.70.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is STTK a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Shattuck Labs, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is STTK stock overvalued or undervalued?
Valuation metrics for STTK: ROE of -59.2% (sector avg: 15%), net margin of -4,880.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy STTK stock in 2026?
Our dual AI analysis gives Shattuck Labs, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is STTK's free cash flow?
Shattuck Labs, Inc.'s operating cash flow is $-39.9M, with capital expenditures of $71.0K. FCF margin is -3,995.3%.
How does STTK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,880.9% (avg: 12%), ROE -59.2% (avg: 15%), current ratio 11.70 (avg: 2).